A study of lapatinib in combination with oxaliplatin and capecitabine in early HER-2 overexpressing oesophageal and gastric cancers
Read time: 1 mins
Last updated:29th Nov 2010
Is it possible to predict from the pretreatment tumour biopsies whether or not lapatinib will be effective at turning off HER2 signalling?
|Study start date||2010-11-29|